TRVI supply chain intelligence for Trevi Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Trevi Therapeutics, Inc. (TRVI) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| CONTRACT-MANUFACTURERS | CONTRACT-MANUFACTURERS | 90% | A significant portion of the Company’s development activities are outsourced to third parties under agreements, including with CROs and contract manufacturers in connection with the production of cli… |
| CROS | CROS | 90% | A significant portion of the Company’s development activities are outsourced to third parties under agreements, including with CROs and contract manufacturers in connection with the production of cli… |
| CELG-RI | CELG-RI | 72% | inuing voluntary cooperation in other areas. Individual European Union Member States will continue to be responsible for assessing non-clinical (e.g., economic, social and ethical) aspects of health … |
| CELG-RI | CELG-RI | 72% | Reciprocal relationship from CELG-RI graph: Reciprocal relationship from TRVI graph: inuing voluntary cooperation in other areas. Individual European Union Member States will continue to be responsib… |
| GSK | GSK plc | 72% | ions, they may separately regulate drugs as well. While some states automatically classify a drug when the DEA does so, in other states there must be rulemaking or a legislative action. Regulatory au… |
| GSK | GSK plc | 72% | Reciprocal relationship from GSK graph: Reciprocal relationship from TRVI graph: ions, they may separately regulate drugs as well. While some states automatically classify a drug when the DEA does so… |
| MRK | Merck & Co., Inc. | 72% | Reciprocal relationship from MRK graph: Reciprocal relationship from TRVI graph: Reciprocal relationship from MRK graph: Reciprocal relationship from TRVI graph: Reciprocal relationship from MRK grap… |
| MRK | Merck & Co., Inc. | 72% | ions, they may separately regulate drugs as well. While some states automatically classify a drug when the DEA does so, in other states there must be rulemaking or a legislative action. Regulatory au… |
| MS-PK | Morgan Stanley | 72% | Reciprocal relationship from MS-PK graph: Reciprocal relationship from TRVI graph: Reciprocal relationship from MS-PK graph: Reciprocal relationship from TRVI graph: Reciprocal relationship from MS-P… |
| ORANY | ORANY | 72% | r commercial scale manufacturing capabilities. Although we rely on contract manufacturers, we have personnel with experience to oversee our relationships with contract manufacturers. Haduvio is manuf… |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from TRVI graph: r commercial scale manufacturing capabilities. Although we rely on contract manufacturers, we have personnel with ex… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from TRVI graph: ity of these patents. Even if we pursue such enforcement or defense, we will require the cooperation of our licensor… |
| SNYNF | Sanofi | 72% | ity of these patents. Even if we pursue such enforcement or defense, we will require the cooperation of our licensors and cannot guarantee that we would receive it and on what terms. We cannot be cer… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| CELG-RI | CELG-RI | 72% | inuing voluntary cooperation in other areas. Individual European Union Member States will continue to be responsible for assessing non-clinical (e.g., economic, social and ethical) aspects of health … |
| CELG-RI | CELG-RI | 72% | Reciprocal relationship from CELG-RI graph: Reciprocal relationship from TRVI graph: inuing voluntary cooperation in other areas. Individual European Union Member States will continue to be responsib… |
| GSK | GSK plc | 72% | Reciprocal relationship from GSK graph: Reciprocal relationship from TRVI graph: ions, they may separately regulate drugs as well. While some states automatically classify a drug when the DEA does so… |
| GSK | GSK plc | 72% | ions, they may separately regulate drugs as well. While some states automatically classify a drug when the DEA does so, in other states there must be rulemaking or a legislative action. Regulatory au… |
| MRK | Merck & Co., Inc. | 72% | ions, they may separately regulate drugs as well. While some states automatically classify a drug when the DEA does so, in other states there must be rulemaking or a legislative action. Regulatory au… |
| MRK | Merck & Co., Inc. | 72% | Reciprocal relationship from MRK graph: Reciprocal relationship from TRVI graph: ions, they may separately regulate drugs as well. While some states automatically classify a drug when the DEA does so… |
| MS-PE | Morgan Stanley | 72% | Reciprocal relationship from MS-PE graph: Reciprocal relationship from TRVI graph: Reciprocal relationship from MS-PE graph: Reciprocal relationship from TRVI graph: Reciprocal relationship from MS-P… |
| MS-PK | Morgan Stanley | 72% | cant revenue from sales of Haduvio, if ever, we expect to finance our operations through the sale of equity, debt financings or other capital sources, including potential collaborations with other co… |
| MS-PK | Morgan Stanley | 72% | Reciprocal relationship from MS-PK graph: Reciprocal relationship from TRVI graph: cant revenue from sales of Haduvio, if ever, we expect to finance our operations through the sale of equity, debt fi… |
| ORANY | ORANY | 72% | r commercial scale manufacturing capabilities. Although we rely on contract manufacturers, we have personnel with experience to oversee our relationships with contract manufacturers. Haduvio is manuf… |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from TRVI graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from TRVI graph: r commercial scale manufacturing … |
| SNYNF | Sanofi | 72% | ity of these patents. Even if we pursue such enforcement or defense, we will require the cooperation of our licensors and cannot guarantee that we would receive it and on what terms. We cannot be cer… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from TRVI graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from TRVI graph: ity of these patents. Even if we … |
| LEERINK-PARTNERS-LLC | LEERINK-PARTNERS-LLC | 62% | cant revenue from sales of Haduvio, if ever, we expect to finance our operations through the sale of equity, debt financings or other capital sources, including potential collaborations with other co… |
| SVB-SECURITIES-LLC | SVB-SECURITIES-LLC | 62% | cant revenue from sales of Haduvio, if ever, we expect to finance our operations through the sale of equity, debt financings or other capital sources, including potential collaborations with other co… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| TRVI-DEBT | Debt stack $682,000 | 90% | Market cache reports total debt of $682,000. |
| TRVI-DEBT-13115 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2019-12-31. |
| TRVI-DEBT-13114 | Warrants outstanding: 10757000 | 90% | xbrl warrant detail from xbrl 2025-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| TRVI-OWNER-NEA-MANAGEMENT-COMPANY-LLC | NEA Management Company, LLC | 90% | 13F overlay lists NEA Management Company, LLC as top holder; 201 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| CELG-RI | BRISTOL MYERS SQUIBB CO | 100.00 | 1 | ['customer', 'supplier'] |
| MRK | Merck & Co., Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| SNYNF | Sanofi | 100.00 | 1 | ['customer', 'supplier'] |
| ORANY | ORANGE | 100.00 | 1 | ['customer', 'supplier'] |
| MS-PK | Morgan Stanley | 100.00 | 1 | ['customer', 'supplier'] |
| MS-PE | Morgan Stanley | 100.00 | 1 | ['customer'] |
| GSK | GSK plc | 100.00 | 1 | ['customer', 'supplier'] |
| BDRX | Biodexa Pharmaceuticals Plc | 50.00 | 2 | |
| BCDRF | Banco Santander, S.A. | 50.00 | 2 | |
| ADTTF | Advantest Corporation | 50.00 | 2 | |
| BRID | Bridgford Foods Corporation | 50.00 | 2 | |
| CMRE | Costamare Inc. | 50.00 | 2 | |
| ALXO | ALX Oncology Holdings Inc. | 50.00 | 2 | |
| AMXOF | AMERICA MOVIL SAB DE CV/ | 50.00 | 2 | |
| BFRGW | BullFrog AI Holdings, Inc. | 50.00 | 2 | |
| ASBPW | Aspire Biopharma Holdings, Inc. | 50.00 | 2 | |
| BLTE | Belite Bio, Inc | 50.00 | 2 | |
| RSVR | Reservoir Media, Inc. | 50.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 50.00 | 2 | |
| AMZE | Amaze Holdings, Inc. | 50.00 | 2 |